# Scaffold-mediated miRNA-155 inhibition promotes regenerative macrophage polarisation leading to anti-inflammatory, angiogenic and neurogenic responses for wound healing

**Authors:** Juan Carlos Palomeque Chávez, Marko Dobricic, Matthew McGrath, Cian O'Connor, Tara McGuire, Jack Maughan, Adrian Dervan, James E. Dixon, Cathal J. Kearney, Shane Browne, Fergal J. O'Brien

PMC · DOI: 10.1016/j.bioactmat.2026.02.004 · Bioactive Materials · 2026-02-17

## TL;DR

A scaffold that inhibits miRNA-155 promotes healing by reducing inflammation, improving blood vessel growth, and aiding nerve regeneration in chronic wounds.

## Contribution

A novel scaffold-based approach to inhibit miRNA-155 for promoting regenerative wound healing through macrophage polarization and nerve regeneration.

## Key findings

- Scaffold-mediated miRNA-155 inhibition promotes anti-inflammatory M2 macrophage polarization.
- The treatment supports angiogenic outcomes via macrophage secretome.
- In vivo implantation shows successful scaffold integration without vascular disruption.

## Abstract

Chronic wounds represent a significant clinical challenge due to persistent inflammation and impaired nerve regeneration that delay healing. Conventional treatments often yield inconsistent and limited success. Combinatorial strategies that integrate biomaterial scaffolds with gene delivery offer a promising approach to promote tissue repair. MicroRNAs (miRNAs), particularly miRNA-155, are key regulators of wound healing. miRNA-155 is highly expressed in inflammatory conditions and modulates macrophage activation, polarisation, and nerve regeneration. In this context, this study introduces a miRNA-155 inhibitor-activated scaffold designed to modulate the chronic wound environment by inhibiting miRNA-155. miRNA-155 inhibitor complexed GET nanoparticles were incorporated into collagen-glycosaminoglycan (CG) scaffolds. Scaffold-mediated miRNA-155 inhibition in both non-polarised (M0) and pro-inflammatory (M1) macrophages promoted anti-inflammatory (M2) polarisation, confirmed by molecular and protein analysis. The regenerative potential of this macrophage polarisation was validated through inflammatory and angiogenic functional assays with endothelial cells. In parallel, scaffold-mediated miRNA-155 inhibition in dorsal root ganglia (DRG) enhanced axonal regrowth, essential for the synergistic repair of chronic wounds across the skin-nerve axis. In vivo implantation in a chick model demonstrated successful scaffold integration without disrupting vascular development. Collectively, these findings establish the miRNA-155 inhibitor-activated scaffold as a multi-faceted regenerative platform with anti-inflammatory, angiogenic, and neurogenic outcomes for chronic wound healing applications.

Image 1

•miRNA-i-activated scaffolds promote pro-regenerative (M2) macrophage polarisation.•Macrophage secretome from miRNA-i-activated scaffolds support angiogenic outcomes.•Dorsal root ganglia on miRNA-i-activated scaffolds show promising neurogenic outcomes.•In vivo implantation of miRNA-i-activated scaffolds displays successful integration.

miRNA-i-activated scaffolds promote pro-regenerative (M2) macrophage polarisation.

Macrophage secretome from miRNA-i-activated scaffolds support angiogenic outcomes.

Dorsal root ganglia on miRNA-i-activated scaffolds show promising neurogenic outcomes.

In vivo implantation of miRNA-i-activated scaffolds displays successful integration.

## Linked entities

- **Genes:** MIR155 (microRNA 155) [NCBI Gene 406947]

## Full-text entities

- **Genes:** IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, SOCS1 (suppressor of cytokine signaling 1) [NCBI Gene 8651] {aka AISIMD, CIS1, CISH1, JAB, SOCS-1, SSI-1}, MMP1 (matrix metallopeptidase 1) [NCBI Gene 4312] {aka CLG}, ARG1 (arginase 1) [NCBI Gene 383], CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, ICAM1 (intercellular adhesion molecule 1) [NCBI Gene 3383] {aka BB2, CD54, P3.58}, CD80 (CD80 molecule) [NCBI Gene 941] {aka B7, B7-1, B7.1, BB1, CD28LG, CD28LG1}, MIR155 (microRNA 155) [NCBI Gene 406947] {aka MIRN155, miRNA155, mir-155}, NOS2 (nitric oxide synthase 2) [NCBI Gene 4843] {aka HEP-NOS, INOS, NOS, NOS2A}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, MIR223 (microRNA 223) [NCBI Gene 407008] {aka MIRN223, miRNA223, mir-223}, CD86 (CD86 molecule) [NCBI Gene 942] {aka B7-2, B7.2, B70, BU63, CD28LG2, CD86 v6}, INPP5D (inositol polyphosphate-5-phosphatase D) [NCBI Gene 3635] {aka SHIP, SHIP-1, SHIP1, SIP-145, hp51CN, p150Ship}, BCL6 (BCL6 transcription repressor) [NCBI Gene 604] {aka BCL5, BCL6A, LAZ3, ZBTB27, ZNF51}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, VCAM1 (vascular cell adhesion molecule 1) [NCBI Gene 7412] {aka CD106, INCAM-100}, MRC1 (mannose receptor C-type 1) [NCBI Gene 4360] {aka CD206, CLEC13D, CLEC13DL, MMR, MRC1L1, bA541I19.1}, SELP (selectin P) [NCBI Gene 6403] {aka CD62, CD62P, GMP140, GRMP, LECAM3, PADGEM}, TNF receptor-associated factor 6 [NCBI Gene 222344], TRAF6 (TNF receptor associated factor 6) [NCBI Gene 7189] {aka MGC:3310, RNF85}, SELE (selectin E) [NCBI Gene 6401] {aka CD62E, ELAM, ELAM1, ESEL, LECAM2, selectin-e}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, CDH5 (cadherin 5) [NCBI Gene 1003] {aka 7B4, CD144}, COL3A1 (collagen type III alpha 1 chain) [NCBI Gene 396340] {aka collagen}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, MIR146A (microRNA 146a) [NCBI Gene 406938] {aka MIRN146, MIRN146A, miR-146a, miRNA146A}
- **Diseases:** Chronic wounds (MESH:D014947), chronic inflammation (MESH:D007249), skin injury (MESH:D000069836), pain (MESH:D010146), haemostasis (MESH:D020141), diabetes (MESH:D003920), neurotoxicity (MESH:D020258), obesity (MESH:D009765), impaired nerve regeneration (MESH:D015840), epilepsy (MESH:D004827), diabetic foot ulcers (MESH:D017719), atherosclerosis (MESH:D050197), colitis (MESH:D003092), infections (MESH:D007239), Cytotoxicity (MESH:D064420), neuronal toxicity (MESH:D009410), neuropathy (MESH:D009422), axon injury (MESH:D001480)
- **Chemicals:** gold (MESH:D006046), paraffin (MESH:D010232), P (MESH:D010758), PMA (MESH:D013755), DPBS (MESH:C012939), streptomycin (MESH:D013307), carbon (MESH:D002244), Triton X-100 (MESH:D017830), N-hydroxy succinimide (MESH:C001426), palladium (MESH:D010165), H2O (MESH:D014867), Alexa Fluor 555 (MESH:C000608607), ethanol (MESH:D000431), Glutamax (MESH:C054122), S (MESH:D013455), H&amp;E (MESH:D006371), CG-Scr-i (-), heparan sulphate (MESH:D006497), penicillin (MESH:D010406), Alexa Fluor 647 (MESH:C569686), Haematoxylin (MESH:D006416), GAG (MESH:D006025), Hoechst 33342 (MESH:C017807), Alexa Fluor 488 (MESH:C000711379), CO2 (MESH:D002245), Alamar Blue (MESH:C005843), sodium carbonate (MESH:C005686), LPS (MESH:D008070), heparin (MESH:D006493), Eosin (MESH:D004801), 1-ethyl-3-(3-dimethyl aminopropyl)-carbodiimide (MESH:D005022), glucose (MESH:D005947)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Homo sapiens (human, species) [taxon 9606], Gallus gallus (bantam, species) [taxon 9031]
- **Cell lines:** THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006), M0 — Homo sapiens (Human), Familial hypertrophic cardiomyopathy type 26, Induced pluripotent stem cell (CVCL_A6XE)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12926579/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12926579/full.md

## References

82 references — full list in the complete paper: https://tomesphere.com/paper/PMC12926579/full.md

---
Source: https://tomesphere.com/paper/PMC12926579